Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab added to nivolumab-based immunotherapy for metastatic melanoma
ACTRN12617000772347Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of denosumab, nivolumab and ipilimumab in melanoma (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Median progression-free survival and Rate of grade 3 and 4 selected immune-related adverse events. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12617000772347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000772347.